Douglas B. Evans
YOU?
Author Swipe
View article: Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma Open
Therapies targeting the RAF-MEK-ERK pathway are generally considered to have limited efficacy in KRAS mutant cancers. However, specific KRAS mutants exhibit distinct behaviors. Notably, KRASG12R pancreatic ductal adenocarcinoma (PDAC) tumo…
View article: 71 Re-Resection of Locally Recurrent Pancreatic Cancer After Index Pancreatectomy: A Systematic Review and Meta-Analysis
71 Re-Resection of Locally Recurrent Pancreatic Cancer After Index Pancreatectomy: A Systematic Review and Meta-Analysis Open
Aim The role of surgical resection in patients with recurrent pancreatic cancer is unclear. We aimed to evaluate the survival outcomes of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy. Metho…
View article: Persistent elevation of parathyroid hormone after curative parathyroidectomy: A risk factor for recurrent hyperparathyroidism
Persistent elevation of parathyroid hormone after curative parathyroidectomy: A risk factor for recurrent hyperparathyroidism Open
Background Up to 45% of patients may have persistently elevated parathyroid hormone (PTH) levels after curative parathyroidectomy for primary hyperparathyroidism (PHPT), although the clinical significance is unclear. We aimed to assess the…
View article: Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series
Chemotherapy-free treatment targeting fusions and driver mutations in <i>KRAS</i> wild-type pancreatic ductal adenocarcinoma, a case series Open
Background: KRAS wild-type (WT) pancreatic ductal adenocarcinoma (PDAC) represents a distinct entity with unique biology. The therapeutic impact of matched targeted therapy in these patients in a real-world setting, to date, is less establ…
View article: Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy Open
Purpose/Objectives Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify clinical characteristics associated with prolonged overall survival (OS) in patients pr…
View article: FRI177 Cosyntropin Stimulation Testing Is More Selective Than Postoperative Day 1 Basal Cortisol for Diagnosing Secondary Adrenal Insufficiency Following Unilateral Adrenalectomy
FRI177 Cosyntropin Stimulation Testing Is More Selective Than Postoperative Day 1 Basal Cortisol for Diagnosing Secondary Adrenal Insufficiency Following Unilateral Adrenalectomy Open
Disclosure: S.H. Johnson: None. C. Zhang: None. P.T. Hangge: None. T.W. Yen: None. T. Shaik: None. K. Doffek: None. J.W. Findling: None. T.B. Carroll: None. D.B. Evans: None. S. Dream: None. T.S. Wang: None. Background: Secondary adrenal i…
View article: Older Patients With Asymptomatic Primary Hyperparathyroidism: Should Criteria for Surgery Be Expanded?
Older Patients With Asymptomatic Primary Hyperparathyroidism: Should Criteria for Surgery Be Expanded? Open
Context Patients with primary hyperparathyroidism (PHPT) can present with variable signs, symptoms, and end-organ effects. Clinical practice guidelines influence referral for consideration of parathyroidectomy. Objective This study compare…
View article: Supplementary Fig. 1 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 1 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Coverage distribution of the gitBS performed on 300 plasma samples
View article: Supplementary Table 3 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Supplementary Table 3 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA Open
Plasma-biomarker analyses
View article: Supplementary Fig. 17 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 17 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Pan-GI prediction accuracy using various number of DMRs identified from pan-GI vs. healthy plasma sample analysis
View article: Supplementary Fig. 1 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 1 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Coverage distribution of the gitBS performed on 300 plasma samples
View article: Supplementary Fig. 9 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 9 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Hierarchical clustering of PDAC and healthy plasma samples
View article: Supplementary Fig. 11 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 11 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
CRC prediction accuracy using various number of DMRs identified from CRC vs. healthy plasma sample analysis
View article: Supplementary Fig. 3 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 3 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Workflow of model training and test for GI cancer prediction. (a) Initial markers discovery was conducted with 1653 GI cancer and 287 normal tissues. Targeted bisulfite sequencing that covers the initial selected CpG sites was performed on…
View article: Supplementary Table 1 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA
Supplementary Table 1 from Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA Open
Gene-expression analyses
View article: Supplementary Table-S3 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Table-S3 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Supplementary Table-S3
View article: Supplementary Table-S5 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Table-S5 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Supplementary Table-S5
View article: Supplementary Table-S7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Table-S7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Supplementary Table-S7
View article: Supplementary Table-S4 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Table-S4 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Supplementary Table-S4
View article: Data from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Data from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Purpose:DNA methylation alterations have emerged as front-runners in cell-free DNA (cfDNA) biomarker development. However, much effort to date has focused on single cancers. In this context, gastrointestinal (GI) cancers constitute the sec…
View article: Supplementary Table-S7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Table-S7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Supplementary Table-S7
View article: Supplementary Fig. 7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 7 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Hierarchical clustering of GC and healthy plasma samples
View article: Supplementary Fig. 19 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 19 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
Multi-class (sec) prediction accuracy using various number of GI cancer-specific DMRs
View article: Supplementary Fig. 12 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 12 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
HCC prediction accuracy using various number of DMRs identified from HCC vs. healthy plasma sample analysis
View article: Supplementary Fig. 15 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers
Supplementary Fig. 15 from EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers Open
EAC prediction accuracy using various number of DMRs identified from EAC vs. healthy plasma sample analysis